
Q32 Bio appoints new CMO and CDO as it advances alopecia areata drug bempikibart to late-stage trials.
Q32 Bio Inc. has named Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer amid its transition to late-stage clinical development. The company is progressing its drug bempikibart, targeting severe alopecia...





